Evaluate the safety, tolerability, and efficacy of OTX-TKI for intravitreal use in subjects with Neovascular Age-Related Macular Degeneration

Multicenter, double masked, randomized, parallel-group study to evaluate the safety, tolerability, and efficacy of OTX-TKI for intravitreal use in subjects with Neovascular Age-Related Macular Degeneration

Inclusion Criteria:

• Have a diagnosis, within 3 years of screening, of previously treated subfoveal neovascularization (SFNV) secondary to nAMD with leakage involving the fovea, previously treated with documented evidence of an initially favorable clinical response to anti-VEGF therapy (i.e. aflibercept, ranibizumab, brolucizumab, or bevacizumab).
• The macular appearance on OCT is considered to be free of excess intraretinal and/or subretinal fluid as judged by the investigator.
• Must have received at least 3 anti-VEGF injections in the past year.
• Have received the most recent anti-VEGF injection within the past 1-4 weeks prior to screening visit.
• BCVA ETDRS score between 24 and 83 letters (~20/25 to ~20/320 Snellen equivalent)

Exclusion Criteria:

• Have evidence of a scar, fibrosis or atrophy of >50% of the total lesion in the study eye
• Have presence of a disease other than choroidal neovascular membrane (CNVM) due to AMD in the study eye that could affect vision or safety assessments
• Have monocular vision (fellow eye Snellen BCVA is 20/200 or worse